NCT04993625View on ClinicalTrials.gov

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Breast Cancer
Interventions
PROCEDURE

avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy

Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

Asan Medical Center
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Asan Medical Center

OTHER

lead

Jeong Eon Lee

OTHER

NCT04993625 - Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study | Biotech Hunter | Biotech Hunter